Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veritas In Silico Inc. ( (JP:130A) ) has provided an announcement.
Veritas In Silico Inc. and Switzerland-based SpiroChem AG have signed a Memorandum of Understanding to collaborate on discovering and experimentally validating next-generation RNA-modulating small molecules by combining Veritas In Silico’s AI-powered RNA design and analytics platform with SpiroChem’s macrocycle, peptide and peptoid chemistry capabilities. The joint research will focus on novel RNA-binding scaffolds that go beyond traditional drug-design rules, generating high-value experimental data and design criteria that could feed future licensing, partnering and co-development deals, while also contributing to Veritas In Silico’s proprietary pipeline and helping it meet a key growth target for new contracts in fiscal 2025, although no immediate material impact on earnings is expected as costs are already budgeted and no upfront payments are involved.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the Tokyo Stock Exchange Growth market, is a Japan-based biotech company focused on AI-driven RNA-targeted drug discovery. Leveraging its proprietary aibVIS platform and cell experiment techniques, the company develops mRNA-targeted small-molecule therapeutics and aims to build a proprietary pipeline while pursuing collaborative research and licensing opportunities with partners in the pharmaceutical and biotech sectors.
Average Trading Volume: 191,437
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.1B
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.